US FDA prepares to face generic drug labeling rule critics
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is to confront critics of its proposed rule in November 2013 to allow generic drug makers to independently revise their product labeling to add new safety updates before the regulators review or approve such changes – in the same way that brand-name manufacturers do already1-3.
You may also be interested in...
Generic Labeling Rule Defies Predictions, Remains In FDA's Long-Term Pipeline
Policy that would allow generic sponsors to change product labels has been delayed yet again, not spiked completely, even with Commissioner Gottlieb's known opposition to the rule.
Generic Labeling Rule Defies Predictions, Remains In FDA's Long-Term Pipeline
Policy that would allow generic sponsors to change product labels has been delayed yet again, not spiked completely, even with Commissioner Gottlieb's known opposition to the rule.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.